Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL1B | P01584 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22959610 | 0.89 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL31023048 | 0.88 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2053208 | 0.88 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2053211 | 0.88 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL6179000 | 0.88 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23975028 | 0.87 | DDB1 (0.57) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26705684 | 0.86 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22787058 | 0.86 | CRBN (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22959605 | 0.86 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22959607 | 0.86 | DDB1 (0.64) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-03 | — | — | US | disclosed |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-12-23 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| US-20210283261-A1 | Compositions and Methods for Treating ALK-Mediated Cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-09-16 | — | — | US | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | DDB1 480/4885CRBN 330/4885IKZF3 1741/4885 |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | DDB1 473/4885CRBN 421/4885IKZF3 1032/4885 |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | DDB1 1141/4885CRBN 527/4885IKZF3 3509/4885 |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | PTK6, NEK6, GRK6 | DDB1 1733/4885CRBN 871/4885IKZF3 3529/4885 |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | MAP2K2, MAP2K1, MAP2K7 | DDB1 995/4885CRBN 1094/4885IKZF3 2434/4885 |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | DDB1 1141/4885CRBN 527/4885IKZF3 3509/4885 |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | DDB1 103/4885CRBN 185/4885IKZF3 1998/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | DDB1 418/4885CRBN 194/4885IKZF3 1172/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | DDB1 480/4885CRBN 330/4885IKZF3 1741/4885 |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | CDK4, CDK6, CDK2 | DDB1 103/4885CRBN 185/4885IKZF3 1998/4885 |
| US-20210283261-A1 | Compositions and Methods for Treating ALK-Mediated Cancer | ALK, BCR, TP53 | DDB1 576/4885CRBN 54/4885IKZF3 440/4885 |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | MKNK1, MKNK2, MTOR | DDB1 1141/4885CRBN 527/4885IKZF3 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.